Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.
Journal: International journal of cancer
Published: October 03, 2025
Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remission.
Journal: International journal of cancer
Published: September 24, 2025
Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial.
Journal: Journal of hematology & oncology
Published: September 22, 2025
Local Control With Reduced-Dose Radiation Therapy for High-Risk Neuroblastoma: Results From a Prospective Clinical Trial.
Journal: International journal of radiation oncology, biology, physics
Published: August 01, 2025
Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma.
Journal: Pediatric blood & cancer
Published: March 13, 2025
Lesion Analysis of 18F-Metafluorobenzylguanidine PET Imaging in Neuroblastoma.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 09, 2025
Rapid COJEC without myeloablative therapy for high-risk neuroblastoma.
Journal: International journal of cancer
Published: February 18, 2025
Safety observations in neuroblastoma patients undergoing 18 F- m FBG PET.
Journal: Nuclear medicine communications
Published: December 06, 2024
A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete Remission.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 16, 2024
Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 23, 2024
Long Prime-Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer Vaccine.
Journal: Vaccines
Published: April 04, 2024
Evolutionary Strategies AI Addresses Multiple Technical Challenges in Deep Learning Deployment: Proof-of-Principle Demonstration for Neuroblastoma Brain Metastasis Detection.
Journal: Journal of imaging informatics in medicine
Published: March 18, 2024
Last Updated: 09/26/2026